Breaking News

ReachBio Research Labs Offers New Services for ADCs

Includes off-target toxicity and linker stability assays for cytotoxicity evaluation

ReachBio Research Labs is now offering off-target toxicity and linker stability assay services for antibody drug conjugates (ADCs).     ReachBio has developed two distinct assay platforms to assess cytotoxicity caused by ADCs.  The first platform evaluates off-target toxicity using colony-forming cell (CFC) assays to assess effects on erythroid, myeloid or megakaryocyte progenitors using bone marrow derived from human, NHP, rat and mouse.     The second platform focuses on the stability of v...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters